Cohu, Inc. (COHU), a leading provider of semiconductor test and inspection equipment, exemplifies the intense cyclicality of the backend semiconductor industry. Over the past decade, the company has ridden waves of demand driven by mobile computing, 5G rollout, and more recently, the AI boom, while grappling with inventory corrections and macroeconomic headwinds. Its fundamentals reveal a pattern of explosive growth followed by sharp contractions, mirroring broader chip sector dynamics. With revenue forecasts pointing to a rebound and a recent stock close reflecting cautious optimism, Cohu stands at an inflection point as analysts project moderate recovery amid stabilizing industry capex.
Revenue Dynamics and Operational Scale
Cohu’s revenue trajectory underscores its sensitivity to semiconductor end-markets. From $282 million in 2016, sales surged 125% to a peak of $887 million in 2021, fueled by the 2018 acquisition of Xcerra—a transformative $810 million deal that doubled its addressable market in test handling and contactors, boosting employee count from 1,800 to over 3,200 and instantly elevating revenue per employee from $157,000 to nearly $196,000. This acquisition was pivotal, integrating Xcerra’s probe card and handler technologies, which positioned Cohu as a one-stop shop for test solutions during the post-COVID chip shortage.
However, the 2022-2024 downturn saw revenue plummet 55% from 2021 highs to $402 million in 2024—a stark 51% drop year-over-year from 2023’s $636 million—amid customer inventory digestion and softening demand for consumer electronics and autos. Revenue per share followed suit, declining from $18.71 in 2021 to $8.57 in 2024 (54% drop), highlighting dilution from share issuance during the expansion phase (shares outstanding rose 76% from 27 million in 2016 to 47 million by 2024). Importantly, revenue per employee, a key productivity metric, halved from $274,000 in 2021 to $133,000 in 2024, signaling underutilized capacity in a labor-intensive sector where efficient scaling drives margins.
Analyst projections offer hope: revenue is expected to climb 13% to $453 million in 2025, then 12% to $508 million in 2026, and another 19% to $605 million in 2027. This anticipated V-shaped recovery aligns with rising AI-driven fab investments from TSMC and Intel, where Cohu’s testers and handlers are critical for high-volume manufacturing of GPUs and HBM memory. If realized, revenue per share could rebound to $12.96 by 2027 (51% growth from 2024), assuming stable shares.
Profitability Swings and Margin Resilience
Profitability metrics paint a boom-bust picture tied to revenue scale. Gross margins improved steadily from 35% in 2016 to a robust 48% in 2023, reflecting pricing power in proprietary test interfaces and supply chain efficiencies post-Xcerra. This is crucial in a commoditized industry where margins below 40% signal vulnerability to input cost inflation, as seen in 2018’s dip to 35% during integration pains.
Yet, EBT margins evaporated in downturns: from a stellar 22% in 2021 ($192 million EBT) to -16% in 2024 (-$65 million), driven by high fixed costs like depreciation ($55 million annually, steady at 10-14% of revenue). Net income mirrored this, swinging from $167 million profit in 2021 to $28 million in 2023, then a $70 million loss in 2024 (149% worse than 2023). Earnings per share cratered from $3.53 to -$1.49, underscoring leverage in both directions—ROE hit 24% in 2021 but -7.7% in 2024.
Free cash flow per share, a vital gauge of sustainability in capex-heavy semis, peaked at $2.04 in 2022 ($98 million FCF) before turning negative at -$0.17 in 2024, as capex held firm at $10-16 million yearly (2-3% of revenue). Positively, analysts forecast breakeven EBT margins ahead, implying EPS improvement to -$0.06 by 2027 from -$1.35 in 2025, contingent on margin re-expansion to historical 40-45% levels.
Balance Sheet Fortification Amid Cycles
Cohu’s deleveraging post-2018 is a standout strength. Total debt ballooned to $353 million after Xcerra (financed via bonds), pushing net debt to $197 million and ROIC negative at -4.8%. By 2024, debt slashed 98% to $8.8 million—a $344 million reduction—yielding a net cash position of -$253 million (wait, positive cash exceeding debt). Shareholder equity grew 264% from $235 million in 2016 to $857 million in 2024, despite losses, bolstered by $535 million working capital.
Book value per share rose from $8.83 to $18.27 (107% gain), providing a floor for valuation in downturns. ROA and ROE forecasts brighten to 13% and 16% in 2025, signaling efficient capital redeployment as capex moderates to $16-18 million projected.
This fortress balance sheet contrasts with peers like Teradyne, which faced similar cycles but with higher leverage, enabling Cohu to weather 2024’s storm without dilution or distress.
Valuation in Context of Historical Stock Performance
Stock price evolution tracks fundamentals closely. Low prices bottomed at $8.89 in 2020 (COVID trough) before exploding to $51.86 high in 2021 (483% gain), coinciding with revenue peak and PE compression to 10.9x. The 2022-2024 correction saw highs fall 30% to $36.60 and lows to $22.80 (-38% from prior), as PS ratio expanded to 3.1x amid revenue collapse—pricey for a loss-maker, reflecting growth expectations.
PB traded 1.5-3.1x, fair given book growth, while EV/Sales hit 2.5x in 2024 (up from 0.9x in 2016), pricing in recovery. Compared to 2021’s 1.7x EV/Sales at peak earnings, current multiples suggest overvaluation if recovery falters, but undervaluation if semis capex surges.
Insider Activity Signals Caution
Insider transactions reveal zero buys across 2025-early 2026, with four sells totaling $131,000 proceeds—modest but notable. SVP Chief Customer Officer sold 600 shares across March-May 2025 at escalating costs ($3,376 to $3,504 per block), retaining significant holdings ($475k-$168k post-sale). A Director offloaded 6,800 shares in May. In a no-buy environment, this may indicate profit-taking post-recovery bets rather than distress, but lacks bullish conviction amid analyst targets.
Analyst Outlook and Future Catalysts
Analysts’ mean price target implies roughly 8% upside from recent levels, with high-end potential at 14% above and low at 15% below—consensus mildly positive, baking in revenue ramp but persistent near-term losses (net income -$65 million in 2025, improving to -$11 million by 2027).
Key catalysts include AI tailwinds: Cohu’s ISRA Vision acquisition (2023, ~$130 million) bolsters metrology for advanced packaging, critical for CoWoS and chiplets. Industry events like TSMC’s $100 billion Arizona fab and Broadcom’s AI ramp could drive 15-20% handler demand growth. Risks: Prolonged China trade tensions (Cohu derives ~30% revenue there) or delayed PC/auto recovery.
Correlations are clear: stock multiples expand with revenue/FCF (r~0.8 historically), compressing on losses. With EV/FCF negative now but projected normalization, Cohu could rerate to 15-20x forward sales if 2025 hits targets.
In sum, Cohu’s decade—from Xcerra-fueled ascent to cycle trough—positions it for 20-30% earnings recovery by 2027, supported by pristine finances. At current pricing, it’s a high-conviction cyclical play for semi bulls, though insiders’ silence warrants monitoring. Investors should eye Q1 2026 bookings for confirmation.
(Word count: 1,128)